|
FDA Reviewer Supports Cardiokine Low-Sodium Drug for One of Two Proposed Indications
Cardiokine’s lixivaptan should be approved to treat low sodium levels associated with syndrome of inappropriate antidiuretic hormone (SIADH), an FDA reviewer says.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives